Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kronos Bio IncfiledCriticalKronos Bio Inc
Priority to CL2021001093ApriorityCriticalpatent/CL2021001093A1/en
Publication of CL2021001093A1publicationCriticalpatent/CL2021001093A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Un compuesto de fórmula (I), como se muestra en el pliego de reivindicaciones, o una sal farmacéuticamente aceptable del mismo. Una composición que comprende dicho compuesto o sal. Un método para tratar enfermedades mediadas por CDK-9, que comprende administrar a un sujeto dicho compuesto o dicha composición.A compound of formula (I), as shown in the specification, or a pharmaceutically acceptable salt thereof. A composition comprising said compound or salt. A method of treating CDK-9 mediated diseases, which comprises administering said compound or composition to a subject.
CL2021001093A2021-04-272021-04-27
Compounds, compositions, and methods to modulate cdk9 activity
CL2021001093A1
(en)
Compound 2-methyl-1- (phenylsulfonyl) -4- (piperazin-1-yl) -1h-benzimidazole, which is a 5-hydroxytryptamine-6 ligand; its pharmaceutical composition; 5-ht6 activity modulator; its use in the treatment of disorders of the central nervous system, such as psychosis, anxiety, depression, epilepsy, among others.